D15Combination of duligotuzumab, anti HER3 antibody or...

Annals of Oncology 2017 / 10 Vol. 28; Iss. suppl_6

D15Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells

Laterza, M M, Ciaramella, V, Morgillo, F, Belli, V, Petrillo, A, Tirino, G, Pompella, L, Savastano, B, Pappalardo, A, Orditura, M, Ciardiello, F, De Vita, F
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx425.014
Date:
October, 2017
File:
PDF, 81 KB
2017
Conversion to is in progress
Conversion to is failed